Back دوكسازوسين Arabic Docsasosin Mesylad Welsh Doxazosin German Doxazosina Spanish دوکسازوسین Persian Doxazosine French דוקסאזוסין HE Doksazosin Croatian Doxazozin Hungarian Doksazosin ID
 | |
 | |
| Clinical data | |
|---|---|
| Pronunciation | /dɒkˈseɪzəsɪn/ dok-SAY-zə-sin OR /ˌdɒksəˈzoʊsɪn/ DOK-sə-ZOH-sin |
| Trade names | Cardura, Carduran, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a693045 |
| License data | |
| Routes of administration | By mouth |
| Drug class | α1 blocker |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 65% |
| Protein binding | 98% |
| Metabolism | Liver |
| Elimination half-life | 22 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.128.642 |
| Chemical and physical data | |
| Formula | C23H25N5O5 |
| Molar mass | 451.483 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD).[1][2] For high blood pressure, it is a less preferred option.[2] It is taken by mouth.[2]
Common side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain.[2] Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism.[2][3] It is a selective α1-adrenergic blocker in the quinazoline class of compounds.[2]
Doxazosin was patented in 1977 and came into medical use in 1988.[4] It is available as a generic medication.[3] In 2021, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[5][6]
A 2021 study associated doxazosin with decelerated biological aging in humans and confirmed its causal role in longevity in C. elegans.[7]
- ^ a b "Cardura- doxazosin mesylate tablet". DailyMed. Retrieved 18 June 2021.
- ^ a b c d e f "Doxazosin Mesylate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 17 March 2019.
- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 765. ISBN 9780857113382.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 455. ISBN 9783527607495.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Doxazosin - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- ^ McIntyre RL, Rahman M, Vanapalli SA, Houtkooper RH, Janssens GE (2021). "Biological Age Prediction From Wearable Device Movement Data Identifies Nutritional and Pharmacological Interventions for Healthy Aging". Frontiers in Aging. 2: 708680. doi:10.3389/fragi.2021.708680. PMC 9261299. PMID 35822021.